Standardization of flow cytometric minimal residual disease assessment in international clinical trials. A feasibility study from the European Myeloma Network

por op Bruinink, Davine Hofste, Oliva, Stefania, Rihova, Lucie, Schmitz, Alexander, Gilestro, Milena, te Marvelde, Jeroen, Kralova, Romana, Høholt, Helle, Broijl, Annemiek, Johnsen, Hans Erik, Hajek, Roman, Boccadoro, Mario, Sonneveld, Pieter, Omedè, Paola, van der Velden, Vincent H.J.
Publicado 2020